Background. The Japan integrated staging (JIS) score is recognized to be useful in managing hepatocellular carcinoma (HCC). We evaluated the effects of the causative virus in patients stratified by this system. Method...Background. The Japan integrated staging (JIS) score is recognized to be useful in managing hepatocellular carcinoma (HCC). We evaluated the effects of the causative virus in patients stratified by this system. Methods: We compared clinic opathologic features, cumulative and tumor-free survival rates, and causes of death between 301 hepatitis C virus-positive patients (HCV group) and 60 hepatitis B virus-positive patients (HBV group). Results. Among patients with low JIS scores (0 or 1), the proportions of patients with high aspartate and alanine ami notranferase activities, moderate-to-severe active hepatitis, and with cirrhos is were significantly higher in the HCV than in the HBV group. Among patients wi th high JIS scores (2 to 4), the proportion with moderate-to-severe active hep atitis was also significantly higher in the HCV group. In patients with low JIS scores, those in the HCV group had significantly lower tumor-free and cumulativ e survival rates than those in the HBV group. Although no patient in the HBV gro up died of causes other than liver disease (HCC or hepatic failure), some patien ts in the HCV group died of causes other than liver disease. The proportion of p atients who died because of HCC recurrence tended to be higher among patients wi th high JIS scores than among patients with a low JIS score. Conclusions. The ef fects of viral status on survival outcomes are greatest in patients with JIS sco res of 0 or 1.展开更多
文摘Background. The Japan integrated staging (JIS) score is recognized to be useful in managing hepatocellular carcinoma (HCC). We evaluated the effects of the causative virus in patients stratified by this system. Methods: We compared clinic opathologic features, cumulative and tumor-free survival rates, and causes of death between 301 hepatitis C virus-positive patients (HCV group) and 60 hepatitis B virus-positive patients (HBV group). Results. Among patients with low JIS scores (0 or 1), the proportions of patients with high aspartate and alanine ami notranferase activities, moderate-to-severe active hepatitis, and with cirrhos is were significantly higher in the HCV than in the HBV group. Among patients wi th high JIS scores (2 to 4), the proportion with moderate-to-severe active hep atitis was also significantly higher in the HCV group. In patients with low JIS scores, those in the HCV group had significantly lower tumor-free and cumulativ e survival rates than those in the HBV group. Although no patient in the HBV gro up died of causes other than liver disease (HCC or hepatic failure), some patien ts in the HCV group died of causes other than liver disease. The proportion of p atients who died because of HCC recurrence tended to be higher among patients wi th high JIS scores than among patients with a low JIS score. Conclusions. The ef fects of viral status on survival outcomes are greatest in patients with JIS sco res of 0 or 1.
